CRISPR/Cas9 players create an IP alliance as the war with Editas heats up
Some of the most prominent players in the gene editing field have created an IP-sharing alliance on their CRISPR-Cas9 tech, and Editas $EDIT is conspicuously absent from the club.
The agreement aligns CRISPR Therapeutics, Intellia, Caribou Biosciences and ERS Genomics in what they call a “global cross-consent and invention management agreement” for their IP. And the gene-editing club plans to coordinate their defense of technology emerging from the labs of Emmanuelle Charpentier and Berkeley’s Jennifer Doudna.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.